they carry Aldurazyme Side Effects Generic Name: laronidase Overview Side Effects Dosage Professional Interactions More Pregnancy Warnings User Reviews Support Group Q & A Pricing & Coupons Note: This document contains side effect information about laronidase. Some of the dosage forms listed on this page may not apply to the brand name Aldurazyme. For the Consumer Applies to laronidase: intravenous solution Along with its needed effects, laronidase (the active ingredient contained in Aldurazyme) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention. Check with your doctor or nurse immediately if any of the following side effects occur while taking laronidase: More common Abdominal or stomach pain accumulation of pus back pain black, tarry stools bleeding gums blood in urine or stools blurred vision chest pain chest tightness chills clay-colored stools confusion dark urine dizziness drowsiness facial swelling faintness fast, pounding, or irregular heartbeat or pulse fever flushing headache hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at injection site itching lightheadedness when getting up from a lying or sitting position suddenly loss of appetite nausea or vomiting pale skin pinpoint red spots on skin shortness of breath skin rash sweating swollen, red, or tender area of infection trouble breathing unpleasant breath odor unusual bleeding or bruising unusual tiredness or weakness vomiting of blood yellow eyes or skin Less common Cough difficulty breathing itching skin large, hive-like swelling on face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs noisy breathing redness of skin tightness in chest wheezing Some side effects of laronidase may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them: More common Bleeding, blistering, burning, coldness, or discoloration of skin blindness body aches or pain burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings decreased vision diarrhea difficulty in moving ear congestion feeling of pressure loss of voice muscle pain or stiffness nasal congestion overactive reflexes pain in joints runny nose sneezing sore throat swelling of legs and feet swelling or puffiness of face varicose or spider veins For Healthcare Professionals Applies to laronidase: intravenous solution General The most frequently reported infusion reactions included pyrexia, chills, blood pressure, increased, tachycardia, and oxygen saturation decreased. The most frequently reported adverse reactions included rash, upper respiratory tract infection, injection site reaction, hyperreflexia, paresthesia, flushing, and poor venous access. [ Ref ] Hypersensitivity Common (1% to 10%): Anaphylactic reaction [ Ref ] Other Very common (10% or more): Infusion reactions (up to 49%), pyrexia (up to 30%), otitis media (20%), chills (up to 20%), central venous catheterization required for infusion (15%), oxygen saturation decreased (up to 10%) Common (1% to 10%): Chest pain, face edema, gravitational/dependent edema, abscess, feeling hot, feeling cold, influenza-like illness, body temperature increased Frequency not reported: Laryngeal edema, extravasation Postmarketing reports: Fatigue [ Ref ] The most common adverse reactions were infusion reactions; the frequency decreased over time with continued use, and most were classified as mild to moderate in severity. The majority of infusion reactions requiring intervention were ameliorated with slowing of the infusion rate, temporarily stopping the infusion, with or without administering additional antihistamines and/or antipyretics. [ Ref ] Gastrointestinal Very common (10% or more): Nausea, abdominal pain/discomfort Common (1% to 10%): Vomiting, diarrhea [ Ref ] Immunologic In clinical trials, 99 of 102 patients developed IgG antidrug antibodies. No correlation was demonstrated between presence of antidrug antibodies and therapeutic response or the occurrence of allergic reactions. There was also no consistent association between presence of antibodies that neutralize enzymatic activity and therapeutic response. The potential for antibody neutralization of cellular uptake has not been evaluated. There were 9 patients collectively in clinical studies who experienced severe infusion reactions and were subsequently tested for drug specific IgE antibodies and complement activation. Following testing, 1 of the 9 patients had an anaphylactic reaction consisting of urticaria and airway obstruction and tested positive for both drug specific IgE binding antibodies and complement activation. In a separate open-label study of patients 5 years and younger, none tested positive for IgE. The clinical significance of IgE antibodies has not been established. [ Ref ] Very common (10% or more): Antidrug antibody development (97%) Postmarketing reports: Anaphylactic shock, IgE antibody development, compliment activation [ Ref ] Dermatologic Very common (10% or more): Rash (up to 36%) Common (1% to 10%): Angioedema, urticaria, pruritus, hyperhidrosis, alopecia, cold sweat Frequency not reported: Erythema [ Ref ] Local Very common (10% or more): Injection site reaction (up to 18%) Common (1% to 10%): Injection site pain [ Ref ] Respiratory Very common (10% or more): Upper respiratory tract infection (32%) Common (1% to 10%): Respiratory distress, dyspnea, cough, wheezing, pulmonary crepitation Frequency not reported: Bronchospasm, hypoxia, tachypnea, respiratory arrest Postmarketing reports: Respiratory failure, pneumonia [ Ref ] Cardiovascular Very common (10% or more): Flushing (up to 23%), poor venous access/vein disorder (14%), blood pressure increased (up to 10%), tachycardia (up to 10%) Common (1% to 10%): Hypotension, pallor, peripheral coldness Frequency not reported: Cyanosis Postmarketing reports: Cardiorespiratory arrest, cardiac failure [ Ref ] Nervous system Very common (10% or more): Hyperreflexia (14%), paresthesia (14%), headache Common (1% to 10%): Dizziness, tremor [ Ref ] Hematologic Common (1% to 10%): Thrombocytopenia [ Ref ] Hepatic Common (1% to 10%): Hyperbilirubinemia, bilirubinemia [ Ref ] Ocular Common (1% to 10%): Corneal opacity [ Ref ] Musculoskeletal Very common (10% or more): Arthropathy, arthralgia, back pain, pain in extremity Common (1% to 10%): Musculoskeletal pain [ Ref ] Psychiatric Common (1% to 10%): Restlessness [ Ref ] References 1. "Product Information. Aldurazyme (laronidase)." Genzyme Corporation, Cambridge, MA. 2. Cerner Multum, Inc. "Australian Product Information." O 0 3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 Some side effects of Aldurazyme may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA . Next Dosage Print this page More about Aldurazyme (laronidase) Side Effects During Pregnancy Dosage Information Drug Interactions Support Group Pricing & Coupons En Español 0 Reviews Add your own review/rating Drug class: lysosomal enzymes Consumer resources Aldurazyme Aldurazyme (Advanced Reading) Professional resources Aldurazyme (AHFS Monograph) Aldurazyme (FDA) Related treatment guides Mucopolysaccharidosis Type I Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.} Drug Status Rx Availability Prescription only B Pregnancy Category No proven risk in humans N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA Manufacturers Genzyme Corporation Sanofi-Aventis U.S. LLC BioMarin Pharmaceutical Inc. Drug Class Lysosomal enzymes Related Drugs Mucopolysaccharidosis Type I n/a Aldurazyme Rating No Reviews - Be the first! No Reviews - Be the first! Not Rated - Be the first!} } sales space
planning stage Aldurazyme Side Effects premier
EmoticonEmoticon